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Improvement in the clinical outcome of
patients with cancer comes in small steps.
These steps are being taken by different pro-
fessionals in different aspects of care:
improved diagnosis, better surgery, new
drugs, more complete ancillary care and, last
but not least, a greater involvement of
patients in decision-making. Many small steps
will result in a big move forward, provided
that the steps are in the right direction.
When a diagnostic test fails to identify the
correct patients for a certain drug the
outcome may be negatively affected. This
calls for quality across the whole clinical
team and the activities that support the
patient.
In April this year, for the ﬁfth consecutive
year, representatives of all stakeholders
involved in promoting accurate diagnostic
testing for anticancer drug selection gath-
ered in Naples in order to optimise the
chance that patients will have an appropriate
test which forms the basis for the decision of
administering targeted treatment. These sta-
keholders include pathologists, molecular
biologists, quality managers, medical oncolo-
gists, representatives of the pharmaceutical
companies, vendors of synthetic controls for
diagnostic methods and equipment, patients
and representatives of the European
Medicines Agency (EMA). This focused
meeting, with no more than 50–70 partici-
pants, has already proven to be effective by
creating guidelines on a key aspect of quality
in the chain: external quality assessment
(EQA).1 The Naples meeting is organised by
the Italian Association of Medical Oncology
(AIOM) together with the European Society
of Pathology (ESP) and the Italian
Association of Surgical Pathology (SIAPEC-
IAP), with the endorsement of the European
Society of Medical Oncology (ESMO). The
2016 meeting celebrated its ﬁfth anniversary,
and the start of IQN Path ASBL, a new
organisation that brings all stakeholders
together who are involved with EQA.
EQA is one of the activities that measures
and evaluates test performance in laborator-
ies. It is usually performed by circulating
samples with known characteristics, for
example, KRAS mutation or strong HER2
expression, which are tested in the participat-
ing laboratories so that they can be evaluated
on the quality of testing. This evaluation
includes the actual test result, and also the
turn-around time and reporting of results. It
has been shown repeatedly that EQA leads to
improved quality of testing. This sounds
simple enough, but there are many chal-
lenges: testing methods change rapidly such
as, the recent introduction of next gener-
ation sequencing; the types of material that
need testing now include blood (the
so-called ‘liquid biopsy’); the number of
targets for testing are increasing (like the
evolution of KRAS testing into RAS). These
developments call for coordination and har-
monisation. EQA provides a quality mark to
laboratories that perform testing; therefore it
is quite important that this quality mark is
reliable. We need to prevent a movement of
laboratories towards an ‘easy’ EQA provider,
like one director of a programme remarked:
“I received a letter from a participant com-
plaining about not passing the bar and threa-
tening to go to another scheme”.
Interestingly enough the director of that
other scheme was present too and remarked
that he received similar letters…..
Fortunato Ciardiello, medical oncologist,
gave an overview on the progress made in
the treatment of colorectal cancer, including
the introduction of targeted therapies, specif-
ically epidermal growth factor receptor-
targeted agents. He pointed out that these
agents do have some effect when the whole
group of patients with colorectal cancer is
being treated, but with limited effect. Based
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on the biology of the tumour and treatment, at ﬁrst
patients with a KRAS-mutated tumour were excluded
from the therapy and later also those who have a NRAS
mutation. This was achieved thanks to several well-
designed retrospective studies and using tissues saved for
testing. With proper selection, the drugs have a much
better cost-beneﬁt proﬁle and are thus a really import-
ant contributor to the better survival of patients with
colorectal cancer. This calls for correct testing which was
shown to be possible but should not be taken for
granted. Results from EQA schemes indicated that there
is a learning curve and that feedback from the organi-
sers results in improvement.2 The interaction of test pro-
viders and oncologists is quite important and chief
medical ofﬁcer, Jean-Yves Douillard proposed to come to
a mutual agreement between IQN Path and ESMO to
take this further.
Concern has arisen about the cost of the new drugs,
even after optimal selection by correct testing.
Francesco Perrone provided an impressive overview to
what the effects of these costly medicines can be. In the
USA, a debate has already started on cancer bankruptcy
and the effects of ﬁnancial strain on quality of life and
even survival. Although these issues are nowadays not
present in most European countries, there is certainly
concern regarding the increasing costs of cancer drugs.
So why are these drugs so costly? The answer is not so
straightforward. Perrone showed that neither the costs
of development or high efﬁcacy are the drivers for high
pricing. Without pointing too strongly towards the
pharmaceutical industry (they do provide important
breakthroughs) he did indicate that Europe needs to
rethink its policy that health is an issue of member
states rather than an issue of the Union: this makes the
negotiation power weak, as is exempliﬁed in an elegant
study from van Harten et al3 which showed the prices of
cancer drugs varies enormously between European
countries and between drugs, no country being gener-
ally better or worse off. Clearly better deals are
possible.
Jola Gore-Booth, representing Europa-colon, provided
a sharp insight in the wishes and stakes of patients: they
want to trust the healthcare system and indeed want
testing to be reliable. She feels that it should not be the
responsibility of patients to look for the laboratory that
provides good testing although she welcomes openness
and transparency. In fact, Jola indicated that she was not
even aware of the variation that exist in quality of testing
and offered to seek projects in which patients, clinicians
and testing facilities can jointly promote improvement.
It was interesting to have a deep insight into how the
EMA, represented by Rosa Giuliani, decides that a new
drug may be allowed in Europe: it needs to have more
beneﬁt than risk, nothing more nothing less. The EMA
does not deal with costs or clinical relevance; indeed the
healthcare system is not part of the responsibilities of
the agency or the European Union for that matter (see
above!). It was very much welcomed that the EMA is
open-minded towards diagnostic tests that accompany
new (and old) drugs; even when there is already a test
available, it is clear that based on experiences from prac-
tice better tests can be developed, leading to better
patient selection.
EQA providers from Italy, France, Spain, the UK,
Germany, Sweden and the European Society for
Pathology provided insights into their way of working
and the results. There were many similarities and experi-
ences but also important differences. How is sample
selection performed, how many difﬁcult samples need
to be chosen and what to do with laboratories to
perform consistently below an acceptable level? The
group decided to create a task force that will come up
with a document that addresses these items, to be pre-
sented at the 2017 meeting and will be steered by Els
Dequeker.
Quite some hours were spent on the challenging topic
of blood-based testing. It is clear that this is a promising
ﬁeld that may result in earlier termination of treatment
that is not effective and that this type of testing can
replace invasive procedures to obtain tissue. Several tech-
niques are already available as well as data from small
patient series. It is already quite clear that there is vari-
ation between techniques and that the logistics of blood
samples, storage and transportation are critical. This
obviously calls for a clever approach to EQA, a task that
also was assigned to a small working group. Based on
experiences from QUIP, the German EQA provider, and
UK NEQAS, and inputs from ESP EQA, GenTiss, AIOM
and EMQN, a guideline on this topic will be written,
coordinated by Manfred Dietel and Sandi Deans.
The most recent progress in the clinical implementa-
tion of liquid biopsy in lung and colorectal carcinoma
were summarised by Jean Yves Douillard and Jesús
García-Foncillas. The plans for an EQA testing on liquid
biopsy under the umbrella of IQN Path were also illu-
strated by Sandi Deans. Results of the pilot phase are
expected in the third-quarter of 2016, and it was
decided to follow-up the EQA with the preparation of
guidelines for liquid biopsy testing. This task was
assigned to a working group lead by Sandi Deans, Jose
Costa and Nicola Normanno.
The ﬁrst four meetings on EQA had focused on
DNA-based techniques, but it is clear that other tissue-
based techniques are relevant as well: presentations
from NordiQC and UK NEQAS on the results from
EQA in immunohistochemistry indicated that more har-
monisation is urgently needed. Although this technology
is quite a bit older than DNA analyses, there are recent
developments in the technology and the possibility for
computer-aided evaluation that a new era is approach-
ing: reliable quantiﬁcation of protein in tissue context.
Experiences with the more traditional approaches,
however, show the need for stringent EQA. A working
group for EQA for immunohistochemistry within the
IQN Path was formed, led by Mogens Vyberg and Keith
Miller.
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Next generation sequencing techniques are rapidly
replacing more traditional methods of determining
DNA alterations that indicate eligibility for certain ther-
apies. In fact, the methodology is now so mature that a
manuscript could be discussed and that, with a few
alterations, will be submitted for publication. This is
quite a success from the 2015 meeting, when the task to
create this was assigned to a group led by Sandi Deans.
It is to be expected that this expert opinion document
will serve the community well so that soon reliable tar-
geted testing will become available for the majority of
patients with cancer in Europe.
The presence of the industry was a great asset to the
success of the meeting, since they were given the ﬂoor
to show their solutions, which were often very promis-
ing and at the same time very practical. Although, or
maybe thanks to, this is a very competitive ﬁeld there
was a clear mission for the whole group: to obtain a
correct diagnosis for every patient at a very high pos-
sible quality at a very low possible price. All had agreed
that EQA is an integral part of the whole process, a
challenge for all scheme providers and for the IQN
Path.
It was a fruitful meeting, not in the least because all
participants were dedicated experts and know one
another better and better. We believe a critical factor to
the success of the meeting is that it is not too large
allowing for personal interaction and plenty of discus-
sion. The main risk for the meeting was the ﬁne weather
in beautiful Naples; nevertheless, the content of the
session was such that these were even more tempting
and all remained inside. Without discussion it was
agreed that in 2017 there will be a follow-up meeting.
IQN Path ASBL is a not for proﬁt association regis-
tered in Luxembourg.
The mission of IQN Path is to provide a coordination
platform for EQA providers, testing laboratories, diag-
nostics companies and the pharmaceutical industry to
address common challenges collaboratively and establish
harmonisation and increased uptake of EQA in bio-
marker testing in tissue-based pathology. IQN Path
would like to thank its members and corporate sponsors
for making the platform such as success and particular
thanks to Professor Han van Krieken the president of
IQN Path, the Board and Dr Jacqueline Hall the
Executive Director. For more information please visit the
IQN Path ASBL website: http://www.iqnpath.org
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